July 2019 will see the launch of our second Ending Age-Related Diseases conference at the Frederick P. Rose Auditorium, Cooper Union in New York City. The event was so popular last year that we decided to expand it to two full days of science and biotech business this year.
We will be bringing you the latest aging research, investment, and business knowledge from some of the top experts in the industry. We will be packing two days full of talks from and discussion panels with the people who are developing the technologies that could change the way we regard and treat aging forever.
With just over a month left to grab a lower-cost early bird ticket for the event, we thought that it would be a good opportunity to take a look at what we have in store. We have already announced lots of inspiring speakers from the research and business sectors of the industry, and here are just a few of them.
Inspiring speakers from the aging research field
Dr. Aubrey de Grey has long been a proponent for a repair-based approach to aging, and he famously categorized the key aging processes into seven types and proposed engineering-based solutions for all of them.
Aubrey founded the SENS Research Foundation with the goal of supporting the development of therapies and technologies to end age-related diseases to allow healthier and longer lives.
He is one of the key figures in the industry, and we are delighted to welcome him back for a second year at the conference.
Dr. Vadim Gladyshev is a Professor of Medicine at Brigham and Women’s Hospital, Harvard Medical School, and an Associate Member of the Broad Institute. He is also Director of the Center for Redox Medicine.
Dr. Gladyshev’s lab applies high-throughput and computational approaches to understand the mechanisms of aging, the control of lifespan, and the redox regulation of cellular processes.
His lab recently developed biomarkers of mouse aging based on blood DNA methylation patterns. He is also part of the team that developed the MouseAge biomarker system, an A.I.-based system that uses photographic images of mice to predict their age without the need for invasive testing or harm to the animals.
Dr. Vera Gorbunova is an endowed Professor of Biology at the University of Rochester and a co-director of the Rochester Aging Research Center.
Her research is focused on understanding the mechanisms of longevity and genome stability and on the studies of exceptionally long-lived mammals. She is perhaps most well-known for studying why naked mole rats are so long-lived compared to most other rodents, resist cancer, and do not appear to suffer from the debilitations of aging.
Dr. Gorbunova also pioneered a comparative biology approach to studying aging and identified rules that control the evolution of tumor suppressor mechanisms depending on the species’ lifespan and body mass.
Dr. Alexander Zhavoronkov is the Chief Executive Officer of Insilico Medicine, Inc, a Baltimore-based company using the latest advances in artificial intelligence to promote drug discovery, biomarker development, and aging research.
One of his most notable projects is OncoFinder, an algorithm used to analyze the activity of molecular pathways involved in both normal and pathological conditions, from growth and development to aging and cancer. The algorithm can be used to predict which drugs could prove the most effective in the treatment of cancer, for example, or to determine which pathways are involved in age-related diseases.
He is also part of the team that developed the MouseAge biomarker system.
Dr. Morgan Levine is an Assistant Professor at the Yale School of Medicine. The focus of her work is on developing reliable aging biomarkers by combining different approaches and methodologies from statistical genetics, computational biology, and mathematical demography.
She also possesses extensive experience in tracking age-related epigenetic, transcriptomic, and proteomic changes by using machine learning techniques and using this information to evaluate chronic disease risk stratification and develop ways to measure aging in order to assess the efficacy of potential geroprotectors.
Dr. Mike Bonkowski is a research associate at Dr. David Sinclair’s lab at Harvard Medical School. His expertise includes pharmacology, genetics, glucose and insulin homeostasis, metabolism, and animal physiology. His research focuses on expanding the understanding of the links between metabolism, reproduction, aging, and age-related diseases. Dr. Bonkowski is also the lead of the NAD+ Mouse Project, which we successfully crowdfunded last year on Lifespan.io.
Kelsey Moody is the CEO of Ichor Therapeutics, a startup with a large portfolio of companies involved in different aspects of translational aging research. Kelsey is perhaps best known in the community for his work on LYSOCLEAR, an experimental treatment for age-related macular degeneration that is based on LysoSENS. Kelsey has a background in both business and biochemistry, and Ichor’s portfolio also includes the small-molecule drug discovery company Antoxerene, the strategic fund and accelerator program Grapeseed.Bio, and the protein engineering company RecombiPure.
Biotech industry knowledge
Dr. James Peyer earned his doctorate in stem cell biology at the University of Texas Southwestern in Dallas and has a foot in both the research and investment worlds. James is the founder and managing partner of Apollo Ventures, an early-stage life science investor and biotech company builder that focuses on breakthrough technologies for treating age-related diseases.
He is heavily involved in translational research and has a great deal of experience and knowledge in dealing with the challenges and pitfalls that researchers face in taking new therapies from bench to bedside.
Michael Greve has been a successful entrepreneur since the mid-90s when he and his brother founded web.de, the most popular internet portal in Germany. He went on to found a number of other ventures including the flight booking website flug.de and the last-minute travel site lastminute.de.
Michael developed an interest in life extension after deciding that his lifestyle was not healthy and that he should change it. During his journey towards optimal health and nutrition, his research eventually led him to become interested in the work of Dr. Aubrey de Grey, and he realized that ending age-related diseases and preserving health indefinitely was a potentially achievable goal.
Following this, he created the Forever Healthy Foundation, whose goal is to speed up the development of therapies focused on ending age-related diseases.
To make sure these technologies arrive sooner rather than later, Michael’s company Kizoo Ventures provides mentoring, seed, and early-stage financing for startups that focus on rejuvenation biotech. Kizoo has funded Oisin Biotechnologies, Ichor Therapeutics’ LysoCLEAR, and AgeX Therapeutics, among others.
The early bird gets the worm
We are currently offering a discounted ticket price up until March 31st when the cost increases to the regular entry price. If you would like to join us for two amazing days of science and save some money, now is the ideal time to secure your place.
We will be announcing even more speakers in the coming weeks, as more thought leaders and experts in the field confirm that they will be joining us, so keep an eye on our conference page for more updates soon.
We look forward to seeing you there!
- Researchers from Berkeley have established that SIRT2 prevents overactivation of the NLRP3 inflammasome through ...Posted in: News
- Members of the longevity community often believe that the main reason why there is no significant public support...Posted in: News